

## Studienübersicht des Einflusses von Mistelextrakten auf die Lebensqualität von Krebspatienten Studies on Influence of Mistletoe Extracts on Quality of Life in Cancer Patients

### Studienübersicht

Auerbach, L., V. Dostal, I. Václavik-Fleck, E. Kubista, A. Rosenberger, S. Rieger, W. Tröger and J. M. Schierholz, *Signifikant höherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiven randomisierten doppelblinden Studie*. In: *Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung*. (Ed. R. Scheer, et al.), pp. 543-554, KVC Verlag, Essen (2005).

Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E, Haim N: *Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: A randomised phase II study*. *Eur J Cancer* 2013, 49:1058-1064

Beuth J., B. Schneider, J.M. Schierholz, *Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study*. *Anticancer Res* 28, 523-528 (2008).

Bock, P. R., W. E. Friedel, J. Hanisch, M. Karasmann and B. Schneider, *Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (Viscum album L.) zusätzlich zur konventionellen adjuvanten onkologischen Therapie bei primärem, nicht metastasiertem Mammakarzinom. Ergebnisse einer multizentrischen, komparativen, epidemiologischen Kohortenstudie in Deutschland und der Schweiz*. *Arzneim -Forsch /Drug Res* 54, 456-466 (2004).

Borrelli, E., *Evaluation of the quality of life in breast cancer patients undergoing lectin standardized mistletoe therapy*. *Minerva Medica* 92, 105-107 (2001).

Büssing A., Brückner U., Enser-Weis U., Schnelle M., Schumann A., Schietzel M., Hatzmann W. and J. Hackmann, *Modulation of chemotherapy-associated immunosuppression by intravenous application of Viscum album L. extract (Isador®): a randomised phase II study*. *European Journal for Integrative Medicine* 1, S44-S54 (2008).

Cazacu, M., T. Oniu, C. Lungoci, A. Mihailov, A. Cipak, R. Klinger, T. Weiss and N. Zarkovic, *The influence of Isorel® on the advanced colorectal cancer*. *Cancer Biother Radiopharm* 18, 27-34 (2003).

Dold, U., L. Edler, H. Ch. Mäurer, D. Müller-Wening, B. Sakellariou, F. Trendelenburg and G. Wagner, *Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom*. pp. 1-144, Georg Thieme Verlag, Stuttgart, New York (1991).

Eggermont, A., U. R. Kleeberg, D. J. Ruiter, and S. Suci. *European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b*. In: *American Society of Clinical Oncology Educational Book*, edited by American Society of Clinical Oncology, Baltimore, MD:Lippincott Williams & Wilkins, p. 88-93 (2001).

Enesel, M. B., I. Acalovschi, V. Grosu, A. Sbarcea, C. Rusu, A. Dobre, T. Weiss and K. Zarkovic, *Perioperative application of the Viscum album extract Isorel® in digestive tract cancer patients*. Anticancer Res 25, 4583-4590 (2005).

Friedel, W.E., H. Matthes, and P. R. Bock. *Mistletoe in supportive care in patients with primary non-metastatic colorectal carcinoma*. ASMO Conference Lugano, Switzerland, 5-8 July 2007 (2007).

Friedel, W.E., H. Matthes, P.R.Bock, K.S.Zänker, *Systematic Evaluation of the Clinical Effects of Supportive Mistletoe treatment within Chemo- and/or Radiotherapy Protocols and Long-Term Mistletoe Application in Nonmetastatic Colorectal Carcinoma: Multicenter, Controlled, Observational Cohort Study*. J Soc Integr Oncol 7(4), 137-45 (2009).

Galun D, Tröger W, Reif M, Schumann A, Stankovic N, Milecevic M: *Mistletoe extract therapy versus no antineoplastic therapy in patients with locally advanced or metastatic pancreatic cancer: A randomized clinical phase III trial on overall survival*. ESMO, Viena, 28 September - 2 October 2012.

Grah C: *Misteltherapie bei nichtkleinzelligem Bronchialkarzinom. Randomisierte, offene Phase-II-Studie zur Untersuchung der Verträglichkeit, Sicherheit und Wirksamkeit von Viscum-album-Extrakt in der palliativen, additiven Behandlung des fortgeschrittenen nichtkleinzelligen Bronchialcarcinom*. Dissertation an der Medizinischen Fakultät Charité, Freie Universität Berlin. PhD Thesis. 2010.

Grah C, Matthes B, Happel H, Lemmens H-P: *Randomisierte, offene Phase-II-Studie zur Untersuchung von Viscum album-Extrakt in der palliativen, additiven Behandlung des fortgeschrittenen nichtkleinzelligen Bronchialkarzinoms (NSCLC)*. In: *Die Mistel in der Tumortherapie 3. Aktueller Stand der Forschung und klinische Anwendung*. Edited by Scheer R, Alban S, Becker H, Blaschek W, Kreis W, Matthes H, Schilcher H, Stange R. Essen, KVC Verlag 2013, 389-401

Grossarth-Maticek R. and R. Ziegler, *Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador®)*. Eur J Med Res 13, 107-120 (2008).

Grossarth-Maticek, R. and R. Ziegler, *Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador®)*. Forsch Komplementärmed 14, 140-147 (2007).

Grossarth-Maticek, R. and R. Ziegler, *Wirksamkeit und Unbedenklichkeit einer Langzeitbehandlung von Melanompatienten mit einem Mistelpräparat (Iscador®)*. Schweizerische Zeitschrift für GanzheitsMedizin 19, 325-332 (2007).

Grossarth-Maticek R. and R. Ziegler, *Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (Viscum album L.) extracts Iscador®*. Arzneim -Forsch /Drug Res 57, 665-678 (2007).

Grossarth-Maticek, R. and R. Ziegler, *Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador®)*. Forsch Komplementärmed 13, 285-292 (2006).

Grossarth-Maticsek, R., H. Kiene, S. Baumgartner and R. Ziegler, *Use of Iscador®*, an extract of European mistletoe (*Viscum album*), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. *Altern Ther Health Med* 7, 57-78 (2001).

Heiny, B.M., V. Albrecht, and J. Beuth. *Lebensqualitätsstabilisierung durch Mistellektin-1 normierten Extrakt beim fortgeschrittenen kolorektalen Karzinom*. *Onkologe* 4 (Suppl.1), 35-39 (1998).

Heiny B.M. and V. Albrecht. *Komplementäre Therapie mit Mistellektin-1-normiertem Extrakt. Lebensqualitätsstabilisierung beim fortgeschrittenen kolorektalen Karzinom - Fakt oder Fiktion?* *Med.Welt* 48419-423 (1997).

Heiny, B.M., *Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema)*. *Krebsmedizin* 12 (Sonderdruck), 1-14 (1991).

Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R: Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. *BMC Complement Altern Med* 2012, 12:172

Kim, M.-H., Y.-K. Park, S.-H. Lee, S.-C. Kim, S.-Y. Lee, C.-H. Kim, Y.-K. Kim, K.-H. Kim, H.-S. Moon, J.-S. Song and S.-H. Park, *Comparative study on the effects of a *Viscum album* (L.) extract (mistletoe) and doxycycline for pleurodesis in patients with malignant pleural effusion*. 51th Meeting of The Korean Association of Internal Medicine. Translation by Helixor Heilmittel GmbH. *Korean Journal of Medicine* 57, S121 (1999).

Kleeberg, U. R., S. Suci, E. B. Bröcker, D. J. Ruiter, C. Chartier, D. Liénard, J. Marsden, D. Schadendorf and A. M. M. Eggermont, *Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN- $\alpha$ 2b versus rIFN-g versus Iscador® M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis*. *Eur J Cancer* 40, 390-402 (2004).

Lange, O., Scholz, G. and Gutsch, J. *Modulation der subjektiven und objektiven Toxizität einer aggressiven Chemotherapie mit Helixor*. Unpublished Report (1985).

Lenartz, D., B. Stoffel, J. Menzel, and J. Beuth. *Immunoprotective activity of the galactoside-specific lectin from Mistletoe after tumor destructive therapy in glioma patients*. *Anticancer Res.* 16, 3799-3802 (1996).

Loewe-Mesch A., Kuehn J.H., Borho K., Abel U., Bauer C., Gerhard I., Schneeweiss A., Sohn C., Strowitzki T. and C. Hagens, *Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit*. *Forsch Komplementärmed* 15, 22-30 (2008).

Longhi A, Mariani E, Kuehn JJ: A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients. *Eur J Integr Med* 2009, 1:27-33

Longhi A, Mariani E, Kuehn JJ, Reif M: *A randomized study on post-relapse disease-free survival with adjuvant mistletoe versus oral Etoposide in osteosarcoma patients*. In: *Die Mistel in der Tumorthherapie 3. Aktueller Stand der Forschung und klinische Anwendung*. 5. edition. Edited by Scheer R, Alban S, Becker H, Blaschek W, Kemper FH, Kreis W, Matthes H, Schilcher H, Stange R. Essen, KVC Verlag 2013, 404-413

Matthes H, Friedel WE, Bock PR, Zanker KS: *Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer*. *Curr Mol Med* 2010, 10:430-439

Matthes, H., W. E. Friedel, and P. R. Bock. *Supportive care in pancreatic carcinoma patients treated with a fermented mistletoe (Viscum album L.) extract*. ASMO Conference Lugano, 5-8 July 2007 (2007).

Piao, B. K., Y. X. Wang, G. R. Xie, U. Mansmann, H. Matthes, J. Beuth and H. S. Lin, *Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial*. *Anticancer Res* 24, 303-309 (2004).

Schumacher, K., B. Schneider, G. Reich, T. Stiefel, G. Stoll, P. R. Bock, J. Hanisch, and J. Beuth. *Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrospective cohort study*. *Anticancer Res.* 23, 5081-5088 (2003).

Semiglasov, V.F., V. Stepula, A. Dudov, W. Lehmacher, and U. Mengs. *The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial*. *Anticancer Res.* 24, 1293-1302 (2004).

Semiglasov, V.F., V. Stepula, A. Dudov, J. Schnitker, and U. Mengs. *Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial*. *Anticancer Res.* 26, 1519-1530 (2006).

Steuer-Vogt, M.K., V. Bonkowsky, P. Ambrosch, M. Scholz, A. Neiß, J. Strutz, M. Hennig, T. Lenartz, and W. Arnold. *The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial*. *Eur.J.Cancer* 37, 23-31 (2001).

Steuer-Vogt, M.K., V. Bonkowsky, M. Scholz, C. Fauser, K. Licht, and P. Ambrosch. *Einfluss eines ML-1-normierten Mistelextraktes auf die Lebensqualität bei Patienten mit Kopf-Hals-Karzinomen*. *HNO* 54 (4), 277-286 (2006).

Tröger W., Matijašević M., Ždrale Z., Tisma N. and S. Jezdic, *Additional therapy with mistletoe extracts in breast cancer patients receiving chemotherapy: a prospective randomized open label pilot study*. In: *Die Mistel in der Tumorthherapie 2. - Aktueller Stand der Forschung und klinische Anwendung*. (Ed. Scheer R, et al.), 509-521, KVC-Verlag, Essen (2009).

Tröger, W., S. Jezdic, Z. Zdrale, N. Tisma, H. J. Hamre, and M. Matijasevic. *Quality of Life and Neutropenia in Patients with Early Stage Breast Cancer: A Randomized Pilot Study Comparing Additional Treatment with Mistletoe Extract to Chemotherapy Alone*. *Breast Cancer: Basic and Clinical Research* 3, 35-45 (2009).

Tröger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M: *Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival*. *Eur J Cancer* 2013, 49:3788-3797

Tröger W, Matijašević M, Ždrale Z, Tisma N, Jezdic S: *Additional therapy with mistletoe extracts in breast cancer patients receiving chemotherapy: a prospective randomized open label pilot study*. In: *Die Mistel in der Tumorthherapie 2. - Aktueller Stand der Forschung und klinische Anwendung*. Edited by Scheer R, Alban S, Becker H, Holzgrabe U, Kemper FH, Kreis W, Matthes H, Schilcher H. Essen, KVC-Verlag 2009, 509-521

Tröger W, Zdrale Z, Stanković N, Matijassiević M: *Five-Year Follow-Up of patients with early stage Breast cancer After a Randomized study comparing Additional Treatment with Viscum Album (L.) extract to chemotherapy Alone*. *Breast Cancer* 2012, 6:173

Tröger W, Zdrale Z, Tisma N, Matijasevic M: *Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life*. *Evidence Based Complementary and Alternative Medicine* 2014, In press.

**Letzte Aktualisierung:**

April 2014